155 related articles for article (PubMed ID: 2481883)
21. Placebo-controlled, double-blind trial of hemodilution in peripheral occlusive arterial disease.
Ernst E; Matrai A; Kollar L
Angiology; 1989 May; 40(5):479-83. PubMed ID: 2468300
[TBL] [Abstract][Full Text] [Related]
22. [Intra-arterial infusion treatment with prostaglandin E1 in patients with intermittent claudication].
Rudofsky G
Wien Klin Wochenschr; 1988 Jul; 100(14):484-8. PubMed ID: 3062906
[TBL] [Abstract][Full Text] [Related]
23. [Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride].
Seboldt H
Fortschr Med; 1980 Feb; 98(7):257-60. PubMed ID: 6767648
[TBL] [Abstract][Full Text] [Related]
24. Studies on haematocrit in peripheral arterial disease.
Lowe GD; Saniabadi A; Turner A; Lieberman P; Pollock J; Drury J
Klin Wochenschr; 1986 Oct; 64(19):969-74. PubMed ID: 3784449
[TBL] [Abstract][Full Text] [Related]
25. Blood fluidity and outcome after femoropopliteal percutaneous transluminal angioplasty (PTA): role of plasma viscosity and low platelet count in predicting restenosis.
van der Loo B; Kovacevic T; Krieger E; Banyai S; Banyai M; Amann-Vesti BR; Jagacic D; Rousson V; Koppensteiner R
Clin Hemorheol Microcirc; 2005; 32(2):159-68. PubMed ID: 15764824
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of 2 6% middle-molecular hydroxyethyl starch solutions on elimination kinetics and flow characteristics of blood in volunteers].
Koscielny J; Jung F; Mrowietz C; Pindur G; Förster H; Schimetta W; Kiesewetter H; Wenzel E
Infusionsther Transfusionsmed; 1994 Aug; 21(4):251-9. PubMed ID: 7524833
[TBL] [Abstract][Full Text] [Related]
27. Success of an outpatient claudication group training program for patients with peripheral arterial occlusive disease (PAOD): the Tübingen model.
Klyscz T; Jünger M; Jünger I; Hahn M; Rassner G
Cent Eur J Public Health; 1997 Mar; 5(1):13-20. PubMed ID: 9150999
[TBL] [Abstract][Full Text] [Related]
28. [Hemorrheological factors in the developmental stages of peripheral arterial occlusive diseases].
Artale F; Sergio G; Cramarossa L; Giunti P; Francisci A; Perego MA
Ric Clin Lab; 1983; 13 Suppl 3():411-5. PubMed ID: 6673022
[TBL] [Abstract][Full Text] [Related]
29. Hematocrit as a risk factor for vascular disease.
Kiesewetter H; Jung F; Lazar H; Roggenkamp HG; Leipnitz G; Kiehl R
Klin Wochenschr; 1986 Oct; 64(19):974-8. PubMed ID: 3784450
[TBL] [Abstract][Full Text] [Related]
30. [The clinico-instrumental evaluation of the efficacy of picotamide in treating chronic obstructive arteriopathies of the lower extremities].
Canonico V; Ammaturo V; Guarini P; Tedeschi C; Nunziata G; Nappi A; Forgione L; Rengo F
Minerva Cardioangiol; 1991 Mar; 39(3):75-80. PubMed ID: 1881558
[TBL] [Abstract][Full Text] [Related]
31. Normovolemic hemodilution in peripheral arterial disease.
Rieger H; Köhler M; Schoop W; Schmid-Schönbein H
Ann Clin Res; 1981; 13 Suppl 33():78-83. PubMed ID: 7342848
[TBL] [Abstract][Full Text] [Related]
32. [Hemorheologic, micro- and macrocirculatory effects of hypervolemic hemodilution with middle molecular weight hydroxyethyl starch (Haes 200/0.62; 6 percent)].
Jung F; Waldhausen P; Spitzer S; Mrowietz C; Häuser B; Wenzel E
Infusionstherapie; 1988 Dec; 15(6):265-71. PubMed ID: 2466797
[TBL] [Abstract][Full Text] [Related]
33. [Hemorheologic studies for evaluating microcirculation in patients with peripheral arterial circulatory disorders and diabetes mellitus].
Sternitzky R; Hänsgen K; Podhaisky H; Frank I; Klare M; Preuss EG
Z Gesamte Inn Med; 1986 Oct; 41(19):539-42. PubMed ID: 3811440
[TBL] [Abstract][Full Text] [Related]
34. [Hemorheologic effects of hydroxyethyl starch 200/0.5, dextran 40, oxypolygelatine and full electrolyte solution over 48 hours].
Brehme S; Keysser G; Turowski A; Schmidt HH
Z Gesamte Inn Med; 1993 Oct; 48(10):506-10. PubMed ID: 7504854
[TBL] [Abstract][Full Text] [Related]
35. [Effects of hydroxyethyl-starch on hemorheology in patients with chronic liver disease].
Lao JX; Gu MN; Xiao JF; Lu XM
Di Yi Jun Yi Da Xue Xue Bao; 2005 Apr; 25(4):438-40. PubMed ID: 15837650
[TBL] [Abstract][Full Text] [Related]
36. Vasogen's immune modulation therapy (IMT) improves postischemic foot skin blood flow and transcutaneous pO(2) recovery rates in patients with advanced peripheral arterial occlusive disease.
Edvinsson LI; Edvinsson ML; Angus Deveber G
Int Angiol; 2003 Jun; 22(2):141-7. PubMed ID: 12865879
[TBL] [Abstract][Full Text] [Related]
37. [Walk training and drug therapy in peripheral arterial occlusive disease. A randomized, prospective, placebo-controlled double-blind study].
Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
Dtsch Med Wochenschr; 1987 May; 112(22):873-8. PubMed ID: 3556133
[TBL] [Abstract][Full Text] [Related]
38. [Hemorheologic, micro- and macrocirculatory effects of an infusion of 500 ml of 6% medium molecular weight hydroxyethyl starch (Haes 200,000/0.5)].
Jung F; Waldhausen P; Mrowietz C; Spitzer S; Kiesewetter H; Wenzel E
Infusionstherapie; 1989 Aug; 16(4):148-54. PubMed ID: 2478482
[TBL] [Abstract][Full Text] [Related]
39. [Hemorheologic, micro- and macrocirculatory effects of hypervolemic infusions of middle molecular weight hydroxyethyl starch (10%, 200,000/0.62) in healthy probands].
Scheffler P; Jung F; Mrowietz C; Waldhausen P; Leipnitz G; Häuser B
Infusionsther Klin Ernahr; 1987 Oct; 14(5):233-8. PubMed ID: 2445681
[TBL] [Abstract][Full Text] [Related]
40. [Experiences with the clinical use of iso- and hypervolemic hemodilution in conservative therapy of vascular diseases].
Turowski A; Schmidt H; Sternitzky R; Brehme S; Keysser G; Hiebsch G; Hiebsch U
Vasa Suppl; 1991; 32():338-41. PubMed ID: 1771528
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
